# Sana Biotechnology, Inc.: overview SANA · Nasdaq · CIK 1770121 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sana.md) · [Financials](/companies/sana/financials.md) · [Filings](/companies/sana/filings.md) · [Insiders](/companies/sana/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-269569.md) | not reported | [(0.21)](/filings/0001193125-26-216769.md) | [(0.39)](/filings/0001193125-26-342395.md) | [(0.16)](/filings/0001193125-25-269569.md) | not reported | [(0.17)](/filings/0001193125-26-216769.md) | [(0.22)](/filings/0001193125-26-342395.md) | | Free cash flow | $m | [(55.9) d](/filings/0001193125-25-269569.md) | [(47.6) d](/filings/0001193125-26-088215.md) | [(48.8)](/filings/0001193125-26-216769.md) | [(33.2) d](/filings/0001193125-26-342395.md) | [(29.5) d](/filings/0001193125-25-269569.md) | [(33.5) d](/filings/0001193125-26-088215.md) | [(37.7)](/filings/0001193125-26-216769.md) | [(34.4) d](/filings/0001193125-26-342395.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.14)](/filings/0000950170-24-023119.md) | [(1.43)](/filings/0000950170-25-040254.md) | [(1.46)](/filings/0001193125-26-088215.md) | [(1.16)](/filings/0001193125-26-088215.md) | [(0.96)](/filings/0001193125-26-088215.md) | | Free cash flow | $m | [(281)](/filings/0000950170-24-023119.md) | [(311)](/filings/0000950170-25-040254.md) | [(274)](/filings/0001193125-26-088215.md) | [(257)](/filings/0001193125-26-088215.md) | [(145)](/filings/0001193125-26-088215.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sana/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $130.6m | 37,429,515 | | Reduced −769 | | [Flagship Pioneering, LLC](/funds/1400240.md) | 2026-06-30 | $87.3m | 25,001,856 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $65.4m | 18,750,000 | | New +18,750,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $58.2m | 16,675,173 | | Added +2,434,998 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $39.1m | 11,203,134 | | Added +665,048 | | [CANADA PENSION PLAN INVESTMENT BOARD](/funds/1283718.md) | 2026-06-30 | $35.7m | 10,218,400 | | Reduced −3,500 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.2m | 8,375,421 | | Added +940,697 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $20.1m | 5,748,454 | | Added +2,801,593 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $16.3m | 4,677,959 | | Added +495,986 | | [Marex Group Ltd](/funds/1997464.md) | 2026-06-30 | $13.9m | 3,989,100 | | Reduced −10,000 | ## Recent filings [All 385 filings](/companies/sana/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 12:00 ET | [8-K](/filings/0001193125-26-384405.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-384405 | | 2026-08-10 | 20:11 ET | [10-Q](/filings/0001193125-26-342395.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342395 | | 2026-08-10 | 20:09 ET | [8-K](/filings/0001193125-26-342371.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342371 | | 2026-06-05 | 20:05 ET | [8-K](/filings/0001193125-26-259532.md) | 5.07 Shareholder vote results | 0001193125-26-259532 | | 2026-05-15 | 20:06 ET | [8-K](/filings/0001193125-26-226674.md) | 8.01 Other events | 0001193125-26-226674 | | 2026-05-11 | 20:10 ET | [10-Q](/filings/0001193125-26-216769.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216769 | | 2026-05-11 | 20:08 ET | [8-K](/filings/0001193125-26-216758.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216758 | | 2026-04-24 | 10:20 ET | [DEF 14A](/filings/0001193125-26-174883.md) | Proxy statement, period 2026-06-04 | 0001193125-26-174883 | | 2026-04-24 | 10:00 ET | [8-K](/filings/0001193125-26-174531.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-174531 | | 2026-04-13 | 20:10 ET | [8-K](/filings/0001193125-26-152868.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-152868 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-088215.md), filed Mar 3, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1770121 - Tickers: SANA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.